07:00 , Jun 1, 1999 |  BC Week In Review  |  Company News

Axis Biochemicals, Shield Diagnostics Ltd. deal

The companies completed their previously announced merger to create Axis-Shield (see BioCentury, March 22). Axis Biochemicals ASA (OSE:AXI), Oslo, Norway   Shield Diagnostics Ltd. (LSE:SDG), Dundee, U.K.   Business: Diagnostics/Imaging, Cardiovascular  ...
07:00 , May 10, 1999 |  BioCentury  |  Finance

Centocor coattails

Centocor coattails The persistent rumors about a possible takeout of Centocor (CNTO) by Johnson & Johnson prodded investors to lift the valuations of other independent large-cap biotech companies. Of the 17 companies tracked by BioCentury...
08:00 , Mar 22, 1999 |  BC Week In Review  |  Company News

Axis Biochemicals, Shield deal

The boards of directors of both companies approved the terms of the companies' proposed merger (see BioCentury, March 8). Of the 38 million shares outstanding in the merged company, AXI shareholders will hold 45.6 percent...
08:00 , Mar 8, 1999 |  BC Week In Review  |  Company News

Axis Biochemicals, Shield Diagnostics Ltd. deal

The companies finalized the terms of their proposed merger (see BioCentury Jan. 25). AXI shareholders will receive 1.25 SDG shares for each AXI share and will hold 43 percent of the merged company. Axis Biochemicals...
08:00 , Mar 1, 1999 |  BioCentury  |  Finance

A dry spell is broken

While it had begun to look as if not a single IPO or follow-on would get done this quarter, the spell was finally broken on Friday as Invitrogen (IVGN) raised $45 million in its IPO,...
08:00 , Feb 22, 1999 |  BioCentury  |  Finance

Tough week in Stockholm

By Shaun Brown & Eric Pierce Staff writers The relative insulation of Europe's regional markets has shielded some biotech stocks from the buffeting suffered in the U.S. and in London. But Swedish investors turned away...
08:00 , Jan 25, 1999 |  BC Week In Review  |  Company News

Axis Biochemicals, Shield Diagnostics Ltd. deal

The diagnostic companies agreed in principle to merge, with Axis shareholders receiving one SDG share for each Axis share held. SDG shareholders would own 62 percent and Axis shareholders 38 percent of the combined company,...
08:00 , Jan 25, 1999 |  BioCentury  |  Finance

Genentech pushes past a magic number

While Genentech posted solid 1998 earnings last week, investors will have only one more look at a GNE P&L statement prior to Roche 's June 30 deadline to exercise its option to buy the 34.7...
08:00 , Jan 25, 1999 |  BioCentury  |  Strategy

Going for diagnostic clout

The planned merger between Shield Diagnostics Group plc (LSE:SDG) and Axis Biochemicals AS (OSE:AXI) will create a heart disease testing company valued at about £160 million ($264 million) with enhanced clout when it comes to...
07:00 , Oct 19, 1998 |  BC Week In Review  |  Clinical News

Axis Biochemicals regulatory update

The FDA granted marketing approval for AXI's Homocysteine IMx automated immunoassay for the amino acid homocysteine to predict cardiovascular disease. The product will be distributed in the U.S. by partner Abbott Laboratories (Abbott Park, Ill)...